Concepts (192)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mutation | 6 | 2018 | 497 | 1.170 |
Why?
|
| Adenocarcinoma | 5 | 2018 | 297 | 1.160 |
Why?
|
| Carrier Proteins | 3 | 2017 | 144 | 1.060 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 2 | 2 | 2016 | 2 | 0.990 |
Why?
|
| Colorectal Neoplasms | 3 | 2017 | 219 | 0.990 |
Why?
|
| Glioma | 2 | 2017 | 137 | 0.920 |
Why?
|
| Lung Neoplasms | 3 | 2018 | 423 | 0.900 |
Why?
|
| Neoplasm Invasiveness | 5 | 2017 | 179 | 0.790 |
Why?
|
| Gene Expression Regulation, Neoplastic | 5 | 2018 | 258 | 0.740 |
Why?
|
| Neoplasms | 3 | 2018 | 754 | 0.730 |
Why?
|
| Brain Neoplasms | 2 | 2017 | 637 | 0.680 |
Why?
|
| MicroRNAs | 3 | 2018 | 181 | 0.650 |
Why?
|
| Carcinoma, Pancreatic Ductal | 2 | 2017 | 19 | 0.620 |
Why?
|
| Endometrial Neoplasms | 2 | 2018 | 49 | 0.610 |
Why?
|
| Pancreatic Neoplasms | 2 | 2017 | 131 | 0.570 |
Why?
|
| DNA Polymerase II | 1 | 2018 | 3 | 0.560 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 3 | 1 | 2017 | 4 | 0.530 |
Why?
|
| Neoplasm Staging | 2 | 2018 | 461 | 0.520 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2017 | 23 | 0.510 |
Why?
|
| DNA, Neoplasm | 1 | 2017 | 52 | 0.510 |
Why?
|
| STAT3 Transcription Factor | 1 | 2017 | 23 | 0.510 |
Why?
|
| Chromosomal Instability | 1 | 2016 | 5 | 0.510 |
Why?
|
| Signal Transduction | 3 | 2017 | 727 | 0.500 |
Why?
|
| rac1 GTP-Binding Protein | 1 | 2016 | 5 | 0.500 |
Why?
|
| Neoplasm Metastasis | 2 | 2017 | 222 | 0.500 |
Why?
|
| Autophagy | 1 | 2017 | 55 | 0.490 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2018 | 157 | 0.490 |
Why?
|
| NF-kappa B | 1 | 2016 | 84 | 0.480 |
Why?
|
| Apoptosis | 1 | 2017 | 375 | 0.440 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2017 | 189 | 0.440 |
Why?
|
| Disease Progression | 4 | 2017 | 591 | 0.430 |
Why?
|
| Cell Line, Tumor | 5 | 2018 | 729 | 0.380 |
Why?
|
| Down-Regulation | 3 | 2018 | 131 | 0.380 |
Why?
|
| Humans | 22 | 2018 | 32274 | 0.380 |
Why?
|
| Female | 15 | 2018 | 19942 | 0.310 |
Why?
|
| Cell Movement | 4 | 2016 | 167 | 0.290 |
Why?
|
| Prognosis | 6 | 2018 | 1534 | 0.290 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 3 | 2017 | 81 | 0.280 |
Why?
|
| Mice, Nude | 3 | 2017 | 285 | 0.270 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2018 | 60 | 0.260 |
Why?
|
| Sequence Analysis, DNA | 2 | 2017 | 132 | 0.260 |
Why?
|
| Histone-Lysine N-Methyltransferase | 2 | 2016 | 27 | 0.240 |
Why?
|
| Neoplasm Proteins | 2 | 2017 | 146 | 0.240 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2018 | 821 | 0.230 |
Why?
|
| Mice | 4 | 2018 | 2571 | 0.210 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2018 | 443 | 0.210 |
Why?
|
| Animals | 6 | 2018 | 8199 | 0.210 |
Why?
|
| Male | 8 | 2018 | 19437 | 0.200 |
Why?
|
| Aged, 80 and over | 4 | 2018 | 3898 | 0.190 |
Why?
|
| Genes, p53 | 2 | 2018 | 22 | 0.160 |
Why?
|
| Middle Aged | 7 | 2018 | 11848 | 0.160 |
Why?
|
| Membrane Proteins | 2 | 2018 | 243 | 0.160 |
Why?
|
| Aged | 6 | 2018 | 10260 | 0.160 |
Why?
|
| Gene Deletion | 2 | 2018 | 66 | 0.160 |
Why?
|
| Breast Neoplasms | 2 | 2016 | 762 | 0.160 |
Why?
|
| Tissue Array Analysis | 2 | 2016 | 34 | 0.150 |
Why?
|
| Protein Binding | 2 | 2017 | 244 | 0.150 |
Why?
|
| Lymphatic Metastasis | 2 | 2016 | 168 | 0.150 |
Why?
|
| Transfection | 2 | 2016 | 204 | 0.150 |
Why?
|
| CA-125 Antigen | 1 | 2018 | 8 | 0.150 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2018 | 23 | 0.140 |
Why?
|
| Germ Cells | 1 | 2018 | 11 | 0.140 |
Why?
|
| beta Catenin | 1 | 2018 | 38 | 0.140 |
Why?
|
| DNA Damage | 1 | 2018 | 90 | 0.140 |
Why?
|
| Protein Kinase C-epsilon | 1 | 2017 | 5 | 0.140 |
Why?
|
| Transcription Factor RelA | 1 | 2017 | 22 | 0.130 |
Why?
|
| Esophageal Neoplasms | 1 | 2018 | 39 | 0.130 |
Why?
|
| Adult | 4 | 2018 | 9256 | 0.130 |
Why?
|
| Oncogene Fusion | 1 | 2017 | 1 | 0.130 |
Why?
|
| NFATC Transcription Factors | 1 | 2017 | 5 | 0.130 |
Why?
|
| Immunoglobulins | 1 | 2017 | 13 | 0.130 |
Why?
|
| Vesicular Transport Proteins | 1 | 2017 | 12 | 0.130 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2017 | 9 | 0.130 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2017 | 32 | 0.130 |
Why?
|
| Pathology, Molecular | 1 | 2017 | 15 | 0.130 |
Why?
|
| Cell Adhesion Molecules | 1 | 2017 | 38 | 0.130 |
Why?
|
| Genes, erbB-1 | 1 | 2017 | 14 | 0.130 |
Why?
|
| Clone Cells | 1 | 2017 | 35 | 0.130 |
Why?
|
| Genes, Neoplasm | 1 | 2017 | 17 | 0.130 |
Why?
|
| Genes, ras | 1 | 2017 | 26 | 0.130 |
Why?
|
| Hematologic Diseases | 1 | 2017 | 20 | 0.130 |
Why?
|
| Stomach Neoplasms | 1 | 2018 | 113 | 0.130 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2017 | 81 | 0.130 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2016 | 12 | 0.130 |
Why?
|
| Survival Analysis | 1 | 2018 | 477 | 0.130 |
Why?
|
| Pseudopodia | 1 | 2016 | 2 | 0.130 |
Why?
|
| Cytoskeleton | 1 | 2016 | 20 | 0.130 |
Why?
|
| Proteinase Inhibitory Proteins, Secretory | 1 | 2016 | 1 | 0.130 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2017 | 90 | 0.130 |
Why?
|
| p21-Activated Kinases | 1 | 2016 | 5 | 0.130 |
Why?
|
| Cell Shape | 1 | 2016 | 28 | 0.130 |
Why?
|
| Nasopharyngeal Neoplasms | 1 | 2016 | 5 | 0.130 |
Why?
|
| Neoplasm Transplantation | 1 | 2016 | 73 | 0.120 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2016 | 32 | 0.120 |
Why?
|
| Ovarian Neoplasms | 1 | 2017 | 84 | 0.120 |
Why?
|
| Base Sequence | 1 | 2017 | 252 | 0.120 |
Why?
|
| Neoplastic Stem Cells | 1 | 2017 | 96 | 0.120 |
Why?
|
| Oncogenes | 1 | 2016 | 14 | 0.120 |
Why?
|
| Antibodies, Neutralizing | 1 | 2016 | 23 | 0.120 |
Why?
|
| Doxycycline | 1 | 2016 | 26 | 0.120 |
Why?
|
| DNA Methylation | 1 | 2017 | 144 | 0.120 |
Why?
|
| RNA, Small Interfering | 1 | 2016 | 112 | 0.120 |
Why?
|
| Animals, Newborn | 1 | 2016 | 136 | 0.120 |
Why?
|
| Gene Expression Profiling | 1 | 2017 | 314 | 0.120 |
Why?
|
| Carcinoma | 1 | 2016 | 92 | 0.120 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2018 | 211 | 0.120 |
Why?
|
| Alcohol Drinking | 1 | 2018 | 255 | 0.110 |
Why?
|
| Models, Biological | 1 | 2017 | 408 | 0.110 |
Why?
|
| Young Adult | 2 | 2018 | 2648 | 0.100 |
Why?
|
| Child, Preschool | 1 | 2017 | 1233 | 0.100 |
Why?
|
| European Continental Ancestry Group | 1 | 2017 | 1076 | 0.100 |
Why?
|
| Smoking | 1 | 2017 | 505 | 0.100 |
Why?
|
| Retrospective Studies | 2 | 2018 | 3624 | 0.090 |
Why?
|
| Disease Models, Animal | 1 | 2016 | 1083 | 0.090 |
Why?
|
| Antineoplastic Agents | 1 | 2017 | 595 | 0.090 |
Why?
|
| Disease-Free Survival | 3 | 2016 | 324 | 0.090 |
Why?
|
| Child | 1 | 2017 | 2434 | 0.080 |
Why?
|
| African Americans | 1 | 2017 | 1335 | 0.080 |
Why?
|
| Adolescent | 1 | 2017 | 3517 | 0.080 |
Why?
|
| Sulfides | 2 | 2018 | 27 | 0.070 |
Why?
|
| Caprylates | 2 | 2018 | 27 | 0.070 |
Why?
|
| RNA Interference | 2 | 2017 | 78 | 0.060 |
Why?
|
| Genotype | 2 | 2018 | 702 | 0.060 |
Why?
|
| Proportional Hazards Models | 2 | 2016 | 773 | 0.050 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2018 | 1050 | 0.050 |
Why?
|
| DNA Mutational Analysis | 1 | 2018 | 69 | 0.040 |
Why?
|
| Genetic Association Studies | 1 | 2018 | 146 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-ret | 1 | 2018 | 1 | 0.030 |
Why?
|
| DNA Copy Number Variations | 1 | 2018 | 11 | 0.030 |
Why?
|
| Germ-Line Mutation | 1 | 2018 | 15 | 0.030 |
Why?
|
| Loss of Heterozygosity | 1 | 2018 | 20 | 0.030 |
Why?
|
| Protein Transport | 1 | 2018 | 80 | 0.030 |
Why?
|
| Cell Respiration | 1 | 2018 | 20 | 0.030 |
Why?
|
| Databases, Genetic | 1 | 2018 | 39 | 0.030 |
Why?
|
| Mitoxantrone | 1 | 2018 | 20 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2018 | 19 | 0.030 |
Why?
|
| Mutation, Missense | 1 | 2018 | 47 | 0.030 |
Why?
|
| Retreatment | 1 | 2018 | 42 | 0.030 |
Why?
|
| Cytarabine | 1 | 2018 | 59 | 0.030 |
Why?
|
| Caco-2 Cells | 1 | 2017 | 7 | 0.030 |
Why?
|
| HCT116 Cells | 1 | 2017 | 10 | 0.030 |
Why?
|
| Serine | 1 | 2017 | 11 | 0.030 |
Why?
|
| Acetylation | 1 | 2017 | 14 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2018 | 211 | 0.030 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2018 | 64 | 0.030 |
Why?
|
| Blood Coagulation Factors | 1 | 2017 | 2 | 0.030 |
Why?
|
| Epidermal Growth Factor | 1 | 2017 | 25 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2018 | 257 | 0.030 |
Why?
|
| Bone Marrow | 1 | 2018 | 68 | 0.030 |
Why?
|
| CpG Islands | 1 | 2017 | 44 | 0.030 |
Why?
|
| Cell Nucleus | 1 | 2018 | 111 | 0.030 |
Why?
|
| Transplantation, Heterologous | 1 | 2017 | 109 | 0.030 |
Why?
|
| Sensation Disorders | 1 | 2017 | 11 | 0.030 |
Why?
|
| Lymphopenia | 1 | 2017 | 11 | 0.030 |
Why?
|
| Leucovorin | 1 | 2017 | 19 | 0.030 |
Why?
|
| Hypokalemia | 1 | 2017 | 16 | 0.030 |
Why?
|
| Nerve Tissue Proteins | 1 | 2018 | 124 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2017 | 196 | 0.030 |
Why?
|
| Thrombocytopenia | 1 | 2017 | 30 | 0.030 |
Why?
|
| Neutropenia | 1 | 2017 | 24 | 0.030 |
Why?
|
| Oxygen Consumption | 1 | 2018 | 141 | 0.030 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2018 | 106 | 0.030 |
Why?
|
| Leukocytes | 1 | 2017 | 60 | 0.030 |
Why?
|
| Maximum Tolerated Dose | 1 | 2017 | 62 | 0.030 |
Why?
|
| Hypoalbuminemia | 1 | 2017 | 13 | 0.030 |
Why?
|
| Organoplatinum Compounds | 1 | 2017 | 41 | 0.030 |
Why?
|
| Camptothecin | 1 | 2017 | 45 | 0.030 |
Why?
|
| Recurrence | 1 | 2018 | 285 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2017 | 250 | 0.030 |
Why?
|
| Abdominal Pain | 1 | 2017 | 44 | 0.030 |
Why?
|
| Anemia | 1 | 2017 | 50 | 0.030 |
Why?
|
| Biopsy | 1 | 2018 | 252 | 0.030 |
Why?
|
| Cell Line | 1 | 2018 | 454 | 0.030 |
Why?
|
| Fluorouracil | 1 | 2017 | 79 | 0.030 |
Why?
|
| Hyperglycemia | 1 | 2017 | 85 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2018 | 556 | 0.030 |
Why?
|
| Immunoprecipitation | 1 | 2016 | 33 | 0.030 |
Why?
|
| Immunoblotting | 1 | 2016 | 54 | 0.030 |
Why?
|
| Epigenesis, Genetic | 1 | 2017 | 109 | 0.030 |
Why?
|
| 3' Untranslated Regions | 1 | 2016 | 25 | 0.030 |
Why?
|
| Binding Sites | 1 | 2016 | 144 | 0.030 |
Why?
|
| Mitochondria | 1 | 2018 | 211 | 0.030 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2016 | 83 | 0.030 |
Why?
|
| Sepsis | 1 | 2017 | 164 | 0.030 |
Why?
|
| Genome-Wide Association Study | 1 | 2017 | 543 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2016 | 543 | 0.030 |
Why?
|
| Algorithms | 1 | 2018 | 536 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2018 | 1840 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2016 | 603 | 0.030 |
Why?
|
| Time Factors | 1 | 2016 | 2204 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2018 | 3416 | 0.020 |
Why?
|
| Risk Factors | 1 | 2016 | 3934 | 0.020 |
Why?
|